期刊文献+

VEGF111b的表达载体构建及抗体制备

Construction of VEGF111b expression vector and preparation of VEGF111b antibody
下载PDF
导出
摘要 目的克隆VEGF111b基因,构建真核表达载体pc DNA3.1-VEGF111b,并进行测序,制备VEGF111b多克隆抗体。方法丝裂霉素C诱导处理卵巢癌SKOV3细胞24 h,设计VEGF111b酶切引物,以SKOV3细胞的c DNA为模板,通过PCR得到VEGF111b特异性基因产物,克隆入真核表达载体pc DNA3.1中,获得重组真核表达载体pc DNA3.1-VEGF111b,测序验证。用KLH耦联VEGF111b特异性短肽,制备多克隆抗体,Western blot检测其特异性。结果成功扩增了VEGF111b基因,双酶切、测序鉴定证实目的基因成功克隆到真核表达载体pc DNA3.1中,测序结果与预测完全一致,成功制备了VEGF111b多克隆抗体,使用其多克隆抗体,Western blot能够检测到VEGF111b对应分子量的蛋白条带。结论本研究鉴定了pc DNA3.1-VEGF111b真核表达载体,并验证了VEGF111b多克隆抗体的特异性,为进一步研究VEGF111b蛋白的功能奠定了基础。 Objective To clone the VEGF111 b gene, construct eukaryotic expression system pc DNA3.1-VEGF111 b, sequence VEGF111 b gene, and prepare VEGF111 b polyclonal antibody. Methods With VEGF111b-specific primers and RT-PCR, VEGF111 b gene was amplified from ovarian cancer SKOV3 cells treated with mitomycin C for 24 h. PCR product was cloned into eukaryotic expression vector pc DNA3.1to construct pc DNA3.1-VEGF111 b, and was then sequenced. VEGF111b-specific peptide was connected KLH to prepare the polyclonal antibody. Western blot was used to detect its specificity. Results VEGF111 b gene was successfully amplified by RT-PCR and it was proved to be cloned into pc DNA3.1vector by double digestion with restriction endonuclease and sequencing analysis. We have prepared VEGF111 b polyclonal antibody successfully, and detected protein band of the corresponding molecular weight using the polyclonal antibody by Western blotting. Conclusion This study not only identified eukaryotic expression vector pc DNA3.1-VEGF111 b, but also verified the specificity of VEGF111 b polyclonal antibody, which provides a basis for further research on VEGF111 b function.
出处 《海南医学》 CAS 2014年第22期3277-3280,共4页 Hainan Medical Journal
基金 国家自然科学基金(编号:81250030)
关键词 VEGF111b PCDNA3.1 真核表达 多克隆抗体 VEGF111b pc DNA3.1 Karyotic expression Polyclonal antibody
  • 相关文献

参考文献13

  • 1Liu J, Matulonis UA. New advances in ovarian cancer [J]. Oncolo- gy (Williston Park), 2010, 24(8): 721-728.
  • 2Ledermann JA, Raja FA. Targeted trials in ovarian cancer [J]. Gyne- col Oncol, 2010, 119(1): 151-156.
  • 3Woolard J, Wang WY, Bevan HS, et al. VEGFI65b, an inhibitory vascular endothelial growth factor splice variant: mechanism of ac- tion, in vivo effect on angiogenesis and endogenous protein expres- sion [J]. Cancer Res, 2004, 64(21): 7822-7835.
  • 4Rennel ES, Hamdollah-Zadeh MA, Wheatley ER, et al. Recombi- nant human VEGF165b protein is an effective anti-cancer agent in mice [J]. Eur J Cancer, 2008, 44(13): 1883-1894.
  • 5Rennel ES, Varey AH, Churchill AJ, et al. VEGF (121) b, a new member of the VEGF (xxx) b family of VEGF-A splice isoforms, in- hibits neovascularisation and tumour growth in vivo [J]. Br J Can- cer, 2009, 101(7): 1183-1193.
  • 6Mineur P, Colige AC, Deroanne CF, et al. Newly identified biologi- cally active and proteolysis-resistant VEGF-A isoformVEGF111 is induced by genotoxic agents [J]. J Cell Sci, 2007, 179(6): 1261-1273.
  • 7Keskitalo S, Tammela T, Lyytikka J, et al. Enhanced capillary forma- tion stimulated by a chimeric vascular endothelial growth factor/vas- cular endothelial growth factor-C silk domain fusion protein [J]. Cite Res, 2007, 100(10): 1460-1467.
  • 8Gu F, Li XL, Kong J, et al. VEGFIllb, a new member of VEG- Fxxxb isoforms and induced by mitomycin C, inhibits angiogenesis [J]. Biochem Biophys Res Commun, 2013, 441(1): 18-24.
  • 9Bates DO, Cui TG, Doughty JM, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulat-ed in renal cell carcinoma [J]. Cancer Res, 2002, 62(14): 4123-4131.
  • 10Nowak D, Amin EM, Rennel ES, et al. Regulation of vascular endo- thelial growth factor (VEGF) splicing from pro-angiogenic to an- ti-angiogenic isoforms: a novel therapeutic strategy for angiogene- sis [J]. J Biol Chem, 2010, 285(8): 5532-5540.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部